{"groups":[{"description":"Temozolomide capsules 150 mg/m\\^2 daily on a 7-day on/7-day off schedule for each 28-day cycle. Temozolomide is the only treatment group, and and all participants received the same dosing regimen.","id":"FG000","title":"Temozolomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"69"}],"type":"Progression of disease being studied"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Non-compliance with protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Administrative"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"86"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"86"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}